摘要
目的比较经股静脉中段置入PICC与经股静脉置入CVC在置管困难血液肿瘤婴幼儿中的应用效果。方法回顾性分析2014年1月至2019年6月置管困难肿瘤婴幼儿140例的临床资料,其中67例采用经股静脉中段置入PICC,73例采用经股静脉置入CVC。比较两组导管成本费用、置管时间、导管留置时间和导管并发症发生率的差异。结果 PICC组费用总支出、平均每日维护费用、置管时间低于/短于CVC组,导管留置时间长于CVC组(均P<0.01);两组出口部位感染、堵管和总并发症发生率差异有统计学意义(P<0.05,P<0.01),而导管相关性血流感染、滑脱和静脉炎等发生率差异无统计学意义(均P>0.05)。结论经股静脉中段置入PICC在成本支出、置管时间、留置时间和导管并发症方面均优于股静脉CVC,是置管困难血液肿瘤婴幼儿安全、可行的静脉通路。
Objective To compare the outcomes of PICC placed via the middle segment of the femoral vein and femoral central venous catheter(CVC)in children with hematological malignancies.Methods We retrospectively studied 140 children who were treated in our hospital from January 2014 to June 2019.Sixty-seven cases were placed with PICC via the middle segment of the femoral vein,and 73 cases had femoral CVC.The cost,catheter insertion time,catheter-indwelling-day,and complications were compared.Results The PICC group showed statistically less total cost and average daily maintenance cost,shorter catheter insertion time,and longer catheter-indwelling-day compared with the femoral CVC group(P<0.01 for all).There were significant differences between the two groups in access site infection,catheter blockage and total complications(P<0.05,P<0.01),but no significant differences in catheter-related bloodstream infection,extubation,phlebitis,etc.(P>0.05 for all).Conclusion PICC placed via the middle segment of the femoral vein is superior to femoral CVC in medical cost,catheterization time,indwelling time and catheter related complications.It can be a feasible and safe alternative route of central venous access for children with hematological malignances.
作者
陈珺
管萍
何梦雪
阮海珊
Chen Jun;Guan Ping;He Mengxue;Ruan Haishan(Department of Hematological Malignancy,Shanghai Children′s Medical Center,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China)
出处
《护理学杂志》
CSCD
北大核心
2020年第9期44-47,共4页
Journal of Nursing Science
关键词
血液肿瘤
婴幼儿
静脉通路
股静脉
PICC
中心静脉置管
成本效益
hematological malignancy
children
venous access
femoral vein
peripherally inserted central catheter
central venous catheters
cost-effectiveness